These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2904650)
1. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency. de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650 [TBL] [Abstract][Full Text] [Related]
2. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. de Yebenes JG; Fahn S; Lovelle S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J; Bustos JC; Magariños C; Martinez A Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648 [TBL] [Abstract][Full Text] [Related]
3. PHNO, a novel dopamine agonist, in animal models of parkinsonism. Koller W; Herbster G; Gordon J Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649 [TBL] [Abstract][Full Text] [Related]
4. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease. Garcia de Yebenes J; Fahn S; Mena MA; Pardo B; Casarejos MJ ASAIO Trans; 1988; 34(4):951-7. PubMed ID: 2905893 [TBL] [Abstract][Full Text] [Related]
5. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Nomoto M; Stahl S; Jenner P; Marsden CD Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000 [TBL] [Abstract][Full Text] [Related]
7. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Senthilkumar KS; Saravanan KS; Chandra G; Sindhu KM; Jayakrishnan A; Mohanakumar KP Behav Brain Res; 2007 Nov; 184(1):11-8. PubMed ID: 17765334 [TBL] [Abstract][Full Text] [Related]
8. Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia. de Yébenes JG; Fahn S; Goodman R; Jamrosik Z; Pezzoli G; Popalski S Adv Neurol; 1990; 53():231-8. PubMed ID: 1978516 [No Abstract] [Full Text] [Related]
9. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Sindhu KM; Saravanan KS; Mohanakumar KP Brain Res; 2005 Jul; 1051(1-2):25-34. PubMed ID: 15992782 [TBL] [Abstract][Full Text] [Related]
11. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870 [TBL] [Abstract][Full Text] [Related]
12. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system. Galineau L; Wilson AA; Garcia A; Houle S; Kapur S; Ginovart N Synapse; 2006 Aug; 60(2):172-83. PubMed ID: 16715499 [TBL] [Abstract][Full Text] [Related]
13. Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. Reimers D; Herranz AS; Díaz-Gil JJ; Lobo MV; Paíno CL; Alonso R; Asensio MJ; Gonzalo-Gobernado R; Bazán E J Histochem Cytochem; 2006 Apr; 54(4):457-65. PubMed ID: 16344326 [TBL] [Abstract][Full Text] [Related]
15. Dopamine D1 and D2 receptor-mediated acute and long-lasting behavioral effects of glial cell line-derived neurotrophic factor administered into the striatum. Kobayashi S; Ogren SO; Hoffer BJ; Olson L Exp Neurol; 1998 Dec; 154(2):302-14. PubMed ID: 9878169 [TBL] [Abstract][Full Text] [Related]
16. Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. Liou HH; Chen RC; Tsai YF; Chen WP; Chang YC; Tsai MC Toxicol Appl Pharmacol; 1996 Mar; 137(1):34-41. PubMed ID: 8607139 [TBL] [Abstract][Full Text] [Related]
17. Intrastriatal infusion of lisuride--a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats. May CH; Guilarte TR; Wagner HN; Vogel S Neurodegeneration; 1994 Dec; 3(4):305-13. PubMed ID: 7842301 [TBL] [Abstract][Full Text] [Related]
18. Reductions in spontaneous locomotor activity in aged male, but not female, rats in a model of early Parkinson's disease. Cass WA; Peters LE; Smith MP Brain Res; 2005 Feb; 1034(1-2):153-61. PubMed ID: 15713267 [TBL] [Abstract][Full Text] [Related]
20. The influence of acute and chronic administration of 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline on the function of the nigrostriatal dopaminergic system in rats. Lorenc-Koci E; Antkiewicz-Michaluk L; Kamińska A; Lenda T; Zieba B; Wierońska J; Smiałowska M; Schulze G; Rommelspacher H Neuroscience; 2008 Oct; 156(4):973-86. PubMed ID: 18809471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]